Infectious complications following allogeneic stem cell transplantation: Reduced-intensity vs. myeloablative conditioning regimens

Transplant Infectious Disease

Volumn 15, Issue 1, 2013, Pages 49-59

  Kim, S H ^a   Kee, S Y ^b   Lee, D G ^c,d   Choi, S M ^c   Park, S H ^c   Kwon, J C ^e   Eom, K S ^c,d   Kim, Y J ^c,d   Kim, H J ^c,d   Lee, S ^c,d   Min, C K ^c,d   Kim, D W ^c,d   Choi, J H ^c   Yoo, J H ^c   Lee, J W ^c,d   Min, W S ^c,d  

^a Korea University College of Medicine   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e National Health Insurance Corporation   (South Korea)

Author keywords

Allogeneic stem cell transplantation; Infection; Mortality; Transplantation conditioning

Indexed keywords

BUSULFAN; CARMUSTINE; CEFEPIME; CEFTAZIDIME; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GANCICLOVIR; MELPHALAN; METHOTREXATE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIPERACILLIN PLUS TAZOBACTAM; THIOTEPA;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; APLASTIC ANEMIA; ARTICLE; ASPERGILLOSIS; BACTEREMIA; CANDIDIASIS; CATHETER INFECTION; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG FATALITY; ENGRAFTMENT; FEBRILE NEUTROPENIA; FEMALE; FUSARIOSIS; GASTROINTESTINAL INFECTION; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE SEPSIS; GRAM POSITIVE INFECTION; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HUMAN; INCIDENCE; INFECTION RISK; INFECTIOUS COMPLICATION; INTERMETHOD COMPARISON; LATENT TUBERCULOSIS; LOWER RESPIRATORY TRACT INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SKIN INFECTION; SOFT TISSUE INFECTION; SYSTEMIC MYCOSIS; TUBERCULOSIS; TUBERCULOUS LYMPHADENITIS; VIRUS REACTIVATION; WHOLE BODY RADIATION;

ADULT; BACTERIAL INFECTIONS; COMMUNICABLE DISEASES; FEMALE; HUMANS; MALE; MORTALITY; MULTIVARIATE ANALYSIS; MYELOABLATIVE AGONISTS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIRUS DISEASES;

EID: 84873421566     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12003     Document Type: Article

References (37)

1. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102 (2): 756-762.
2. Martino R, Caballero MD, Canals C, et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 28 (4): 341-347.
3. Hagen EA, Stern H, Porter D, et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis 2003; 36 (1): 9-15.
4. Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002; 8 (9): 512-520.
5. Mohty M, Faucher C, Vey N, et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant 2000; 26 (3): 251-255.
6. Nakamae H, Kirby KA, Sandmaier BM, et al. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15 (6): 694-703.
7. Shigematsu A, Yamamoto S, Sugita J, et al. Increased risk of bacterial infection after engraftment in patients treated with allogeneic bone marrow transplantation following reduced-intensity conditioning regimen. Transpl Infect Dis 2010; 12 (5): 412-420.
8. Su SH, Martel-Laferriere V, Labbe AC, et al. High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17 (7): 1012-1017.
9. Silva Lde P, Patah PA, Saliba RM, et al. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. Haematologica 2010; 95 (7): 1183-1190.
10. Hori A, Kami M, Kim SW, et al. Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation. Biol Blood Marrow Transplant 2004; 10 (1): 65-72.
11. Bachanova V, Brunstein CG, Burns LJ, et al. Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma. Bone Marrow Transplant 2009; 43 (3): 237-244.
12. Martino R, Kerguelen A, Valcarcel D, et al. Reduction of infection-related mortality after allogeneic PBSCT from HLA-identical siblings: longitudinal analysis from 1994 to 2008 at a single institution. Bone Marrow Transplant 2011; 46 (5): 690-701.
13. Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15 (3): 367-369.
14. Luger SM, Ringden O, Zhang MJ, et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012; 47 (2): 203-211. Epub 28 March 2011.
15. Giralt S, Logan B, Rizzo D, et al. Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. Biol Blood Marrow Transplant 2007; 13 (7): 844-852.
16. Park SH, Choi SM, Lee DG, et al. Current trends of infectious complications following hematopoietic stem cell transplantation in a single center. J Korean Med Sci 2006; 21 (2): 199-207.
17. Yoo JH, Lee DG, Choi SM, et al. Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea. Bone Marrow Transplant 2004; 34 (6): 497-504.
18. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34 (6): 730-751.
19. Choi SM, Lee DG, Choi JH, et al. Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea. Int J Hematol 2005; 81 (1): 69-74.
20. Einsele H, Bertz H, Beyer J, et al. Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82 (Suppl 2): S175-S185.
21. Yoo JH, Choi SM, Lee DG, et al. Comparison of the real-time nucleic acid sequence-based amplification (RTi-NASBA) with conventional NASBA, and galactomannan assay for the diagnosis of invasive aspergillosis. J Korean Med Sci 2007; 22 (4): 672-676.
22. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9 (4): 215-233.
23. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15 (6): 825-828.
24. Link H, Bohme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003; 82 (Suppl 2): S105-S117.
25. Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb CD, Young LS. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15 (Suppl 1): S206-S215.
26. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46 (12): 1813-1821.
27. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34 (8): 1094-1097.
28. Leung AY, Yuen KY, Kwong YL. Polyoma BK virus and haemorrhagic cystitis in haematopoietic stem cell transplantation: a changing paradigm. Bone Marrow Transplant 2005; 36 (11): 929-937.
29. Shi-Xia X, Hai-Qin X, Xian-Hua T, Bo F, Xiang-Feng T. Comparison of reduced intensity and myeloablative conditioning regimens for stem cell transplantation in patients with malignancies: a meta-analysis. Clin Transplant 2011; 25 (2): E187-E198.
30. Pinana JL, Martino R, Barba P, et al. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience. Bone Marrow Transplant 2010; 45 (3): 534-542.
31. Baron F, Schaaf-Lafontaine N, Humblet-Baron S, et al. T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation. Transplantation 2003; 76 (12): 1705-1713.
32. Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99 (6): 1978-1985.
33. Maris M, Boeckh M, Storer B, et al. Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Exp Hematol 2003; 31 (10): 941-952.
34. Baron F, Storer B, Maris MB, et al. Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006; 12 (11): 1176-1187.
35. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19 (12): 2304-2312.
36. Ringden O, Labopin M, Ehninger G, et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27 (27): 4570-4577.
37. Narreddy S, Mellon-Reppen S, Abidi MH, et al. Non-bacterial infections in allogeneic non-myeloablative stem cell transplant recipients. Transpl Infect Dis 2007; 9 (1): 3-10.